Pharmacogenetics and Drug Therapy in Psychiatry - The Role of the CYP2D6 Polymorphism

E-ISSN： 1873-4286|13|2|241-250

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.13, Iss.2, 2007-01, pp. : 241-250

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Implementation of CYP2D6 genotyping in psychiatry

By Loovers Harriët M van der Weide Jan

Expert Opinion on Drug Metabolism and Toxicology, Vol. 5, Iss. 9, 2009-09 ,pp. : 1065-1077

Informa Healthcare

Access to resources Recommend Favorite

Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics

By Sehrt Daniel Meineke Ingolf Tzvetkov Mladen Güültepe Senol Brockmööller Jüürgen

Pharmacogenomics, Vol. 12, Iss. 6, 2011-06 ,pp. : 783-795

Future Medicine

Access to resources Recommend Favorite

Genetic Polymorphism in Cytochrome P450 2D6 (CYP2D6): Population Distribution of CYP2D6 Activity

By Neafsey Patricia

Journal of Toxicology and Environmental Health Part B: Critical Reviews, Vol. 12, Iss. 5-6, 2009-05 ,pp. : 334-361

Taylor & Francis Ltd

Access to resources Recommend Favorite

Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity

By LLerena Adriáán Dorado Pedro Peññas-Lledóó Eva M

Pharmacogenomics, Vol. 10, Iss. 1, 2009-01 ,pp. : 17-28

Future Medicine

Access to resources Recommend Favorite

Pharmacogenetics of Tamoxifen: Who Should Undergo CYP2D6 Genetic Testing?

By Higgins Michaela J. Rae James M. Flockhart David A. Hayes Daniel F. Stearns Vered

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 7, Iss. 2, 2009-02 ,pp. : 203-213

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite